WE CLAIM:

1. Use of at least one VEGF antagonist in the manufacture of at least one medicament for the treatment of a patient with an angiogenic eye disorder, wherein the at least one medicament is formulated for administration to the patient in a dosing regime that provides a therapeutically effective amount of the at least one VEGF antagonist, and wherein the dosing regime comprises a dosing cycle that is designed to provide the effective delivery of the at least one VEGF antagonist, wherein the dosing cycle to be provided to the patient comprises:

(i) a therapeutically effective amount of the at least one VEGF antagonist as a single initial dose; and

(ii) a therapeutically effective amount of the at least one VEGF antagonist as at least one secondary dose, wherein the at least one secondary dose is formulated for administration 2 to 4 weeks after the immediately preceding dose; and

(iii) a therapeutically effective amount of the at least one VEGF antagonist as at least one tertiary dose, wherein the at least one tertiary dose is formulated for administration at least 8 weeks after the immediately preceding dose,

and wherein the dosing cycle is repeated for as long as necessary to achieve the desired biological response in the patient.

2. The use of claim 1, wherein only one secondary dose is to be provided to the patient, and wherein the one secondary dose is to be administered 4 weeks after the initial dose of the at least one VEGF antagonist.

3. The use of claim 1, wherein two secondary doses are to be provided to the patient, and wherein each secondary dose is to be administered 4 weeks after the immediately preceding dose.

4. The use of any one of claims 1 to 3, wherein the at least one tertiary dose is to be provided to the patient, and wherein the at least one tertiary dose is to be administered 8 weeks after the immediately preceding dose.

5. The use of any one of claims 1 to 4, wherein at least 5 tertiary doses of the at least one VEGF antagonist are to be provided to the patient, and wherein the first four tertiary doses are to be administered 8 weeks after the immediately preceding dose,
and wherein each subsequent tertiary dose is to be administered 8 or 12 weeks after the immediately preceding dose.

6. The use of any one of claims 1 to 5, wherein the angiogenic eye disorder is selected from the group consisting of age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion and corneal neovascularization.

7. The use of claim 6, wherein the angiogenic eye disorder is age related macular degeneration.

8. The use of any one of claims 1 to 7, wherein the at least one VEGF antagonist is an anti-VEGF antibody or fragment thereof, an anti-VEGF receptor antibody or fragment thereof, or a VEGF receptor-based chimeric molecule.

9. The use of claim 8, wherein the at least one VEGF antagonist is a VEGF receptor-based chimeric molecule.

10. The use of claim 9, wherein the at least one VEGF receptor-based chimeric molecule comprises VEGFR1R2-FcΔC1(a) and which is encoded by the nucleic acid sequence of SEQ ID NO:1.

11. The use of claim 9, wherein the at least one VEGF receptor-based chimeric molecule comprises:
(a) a VEGFR1 component comprising amino acids 27 to 129 of SEQ ID NO:2;
(b) a VEGFR1 component comprising amino acids 130-231 of SEQ ID NO:2; and
(c) a multimerization component comprising amino acids 232-457 of SEQ ID NO:2.

12. The use of any one of claims 1 to 11, wherein all of the doses of the at least one VEGF antagonist are formulated for topical or intraocular administration.

13. The use of claim 12, wherein all of the doses of the at least one VEGF antagonist are formulated for intraocular administration to the patient.

14. The use of claim 13, wherein the intraocular administration is intravitreal administration.

15. The use of claim 14, wherein all of the doses of the at least one VEGF antagonist comprise from about 0.5 mg to about 2 mg of the at least one VEGF antagonist.

16. The use of claim 15, wherein all of the doses of the at least one VEGF antagonist comprise 0.5 mg of the at least one VEGF antagonist.

17. The use of claim 15, wherein all of the doses of the at least one VEGF antagonist comprise 2 mg of the at least one VEGF antagonist.

18. Use of at least one VEGF antagonist in the manufacture of a medicament according to claim 1, wherein:
(i) the single initial dose of the at least one VEGF antagonist formulated for administration to the patient is 2 mg; and
(ii) the at least one secondary dose of the at least one VEGF antagonist formulated for administration to the patient is 2mg; and
(iii) the at least one tertiary dose of the at least one VEGF antagonist formulated for administration to the patient is 2mg.

19. The use according to claim 18, wherein each of the 2mg doses of the at least one VEGF antagonist is formulated for intravitreal injection.

20. The use according to claim 18, wherein each of the 2mg doses of the at least one VEGF antagonist is formulated for intraocular administration.

21. The use according to claim 18, wherein each of the 2mg doses of the at least one VEGF antagonist is formulated for topical administration.